Saul Villeda

Saul Villeda runs the Villeda Lab at the University of California, San Francisco, where his research focuses on the molecular mechanisms underlying brain rejuvenation, including parabiosis (the surgical joining of the circulatory systems of a young and an old animal), young blood plasma administration, and exercise-induced circulating factors [1].

Villeda's most cited scientific contribution is his co-authorship, with Tony Wyss-Coray as senior author, of the 2014 Nature Medicine paper "Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice" [2]. The study found that injecting young mouse blood plasma into old mice improved measures of cognitive function and synaptic plasticity, providing some of the most widely cited experimental support for the idea that circulating factors in young blood can partially reverse specific aging phenotypes in the brain [2]. This paper, alongside contemporaneous parabiosis studies, substantially shaped the last decade of public and scientific interest in young-plasma and parabiosis-adjacent approaches to aging.

An important distinction for readers: it is Wyss-Coray, the paper's senior author and Villeda's collaborator, not Villeda himself, who went on to co-found Alkahest, a company built around therapeutic applications of blood-plasma-derived factors, which was acquired by the Spanish pharmaceutical company Grifols for $146 million in 2021 [3]. Available sources reviewed for this profile do not identify Villeda as a co-founder, equity holder, or paid advisor to Alkahest or to any other commercial young-plasma company; the commercial exploitation of the shared research program appears to run primarily through Wyss-Coray's separate corporate role rather than through Villeda's [3]. Conflating the two collaborators' commercial positions would misrepresent Villeda's own financial relationship to this area of research, and this profile treats that distinction as material.

Villeda's ongoing academic research continues to probe the underlying biology of brain rejuvenation, including identifying specific exercise-induced circulating factors that may replicate some of the cognitive benefits observed with young plasma, without requiring plasma transfer itself [1]. This exercise-factor line of research is potentially more translatable to a therapeutic than whole young-plasma transfusion, since it points toward isolating and eventually synthesizing specific molecules rather than requiring donor plasma.

The original 2014 finding has also drawn some scientific scrutiny and failed or partial replication attempts in subsequent parabiosis literature from other labs, a normal part of a young, actively contested subfield, and readers should treat the initial dramatic headline finding as a genuine but still-maturing area of research rather than a settled mechanism.

The plain takeaway: Villeda's 2014 paper is legitimate, peer-reviewed, highly cited work that opened an entire subfield of aging research, and Villeda himself does not appear to hold the direct commercial stake in young-plasma therapeutics that his more famous co-author Wyss-Coray built through Alkahest, a distinction worth preserving when this research is invoked in commercial or promotional contexts.